Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Goodwin Biotechnology (GBI) has signed an agreement with Rafagen, a provider of cell line engineering for protein and monoclonal antibody drug production, for cell line engineering and biological contract manufacturing.
Subscribe to our email newsletter
GBI is a cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines.
GBI also offers process development services from proof of concept and preclinical through phase II clinical studies.
GBI senior vice president SooYoung Lee said by collaborating with Rafagen for cell line engineering, GBI can expand capabilities as a biological contract manufacturing organization and offer one-stop shopping.
"This enables our clients to overcome challenging projects by working from their cDNA to develop more high productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes," Lee said.